Share This Page
Drug Price Trends for JASMIEL
✉ Email this page to a colleague
Average Pharmacy Cost for JASMIEL
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| JASMIEL 3 MG-0.02 MG TABLET | 50102-0240-21 | 0.15099 | EACH | 2024-12-18 |
| JASMIEL 3 MG-0.02 MG TABLET | 50102-0240-01 | 0.15099 | EACH | 2024-12-18 |
| JASMIEL 3 MG-0.02 MG TABLET | 50102-0240-23 | 0.15099 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Jasmiel
Introduction to Jasmiel
Jasmiel is an AB-rated generic oral contraceptive, containing 3 mg of drospirenone and 0.02 mg of ethinyl estradiol. It is comparable to brand-name contraceptives such as Yaz®, Gianvi™, Loryna®, Lo-Zumandimine™, and Nikki™. This medication is not only used for birth control but also approved to treat moderate acne and symptoms of premenstrual dysphoric disorder (PMDD)[1].
Global Contraceptive Drugs Market Overview
The global contraceptive drugs market is experiencing significant growth. As of 2023, the market size was valued at USD 18.57 billion and is projected to reach USD 37.22 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period of 2024-2032[3][4].
Market Segmentation and Trends
By Product
The oral segment, which includes combined contraceptives like Jasmiel, dominates the market with the highest share. Oral contraceptives are becoming increasingly popular, especially in underdeveloped countries, due to their affordability and therapeutic benefits[4].
By Distribution Channel
The retail pharmacy segment accounts for the largest revenue share in the contraceptive drugs market. This is driven by the public's increasing need for convenient access to contraceptive pills and growing awareness of various contraceptive options[4].
By Region
North America, particularly the United States and Canada, holds the largest share of the contraceptive drugs market. This is attributed to advanced healthcare infrastructure, supportive government policies, and high levels of public awareness about contraceptives. Asia-Pacific is expected to grow at the fastest pace due to increasing public awareness and government initiatives[3][4].
Price Projections and Factors Influencing Pricing
Generic vs. Brand-Name Drugs
As a generic version of well-known brand-name contraceptives, Jasmiel is generally priced lower than its brand-name counterparts. Generic drugs often enter the market after the patent expiration of the original brand-name drug, leading to increased competition and lower prices.
Regulatory and Policy Impacts
The Inflation Reduction Act (IRA) in the U.S. aims to control drug prices by authorizing the Secretary of the Department of Health and Human Services to negotiate prices with manufacturers for high-expenditure, single-source drugs. While this primarily affects brand-name drugs, it can indirectly influence the pricing of generic drugs by setting benchmarks for fair prices[5].
Market Competition
The presence of multiple generic and brand-name contraceptives in the market keeps prices competitive. Companies like Johnson & Johnson Services, Inc., AbbVie Inc., and Bayer AG, which are major players in the contraceptive market, continuously innovate and adjust their pricing strategies to remain competitive[3].
Price Hikes and Inflation
Despite the competitive nature of the market, prescription drug prices, including those for contraceptives, have been increasing faster than the rate of general inflation. For instance, AARP reports that retail prices for commonly used drugs have consistently increased faster than inflation from 2006 to 2020[2].
Specific Pricing for Jasmiel
While specific price projections for Jasmiel are not available, the overall trend in the contraceptive drugs market suggests that prices will remain competitive due to the presence of multiple generic options. However, any significant price hikes would need to be balanced against the backdrop of increasing consumer awareness and regulatory efforts to control drug prices.
Key Takeaways
- Market Growth: The global contraceptive drugs market is expected to grow significantly, driven by increasing awareness and improving healthcare infrastructure.
- Dominance of Oral Contraceptives: The oral segment, including combined contraceptives like Jasmiel, will continue to dominate the market.
- Regional Trends: North America will remain a key market, while Asia-Pacific is expected to grow rapidly.
- Pricing Factors: Generic status, regulatory policies, and market competition will influence the pricing of Jasmiel.
- Price Stability: Despite general trends of price hikes, the competitive nature of the market and regulatory efforts are likely to keep prices stable or moderately increasing.
FAQs
1. What is Jasmiel used for? Jasmiel is used as an oral contraceptive, and it is also FDA-approved to treat moderate acne and symptoms of premenstrual dysphoric disorder (PMDD)[1].
2. How does Jasmiel compare to other contraceptives? Jasmiel is an AB-rated generic version of brand-name contraceptives like Yaz®, Gianvi™, Loryna®, Lo-Zumandimine™, and Nikki™[1].
3. What is the projected growth of the global contraceptive drugs market? The global contraceptive drugs market is projected to grow from USD 18.57 billion in 2023 to USD 37.22 billion by 2032, with a CAGR of 8.2% during the forecast period[3].
4. Which segment dominates the contraceptive drugs market? The oral segment, including combined contraceptives like Jasmiel, dominates the market with the highest share[4].
5. How do regulatory policies impact drug prices? Regulatory policies, such as the Inflation Reduction Act, aim to control drug prices by negotiating with manufacturers, which can indirectly influence the pricing of generic drugs like Jasmiel[5].
Sources
- Afaxys Pharma: Jasmiel® (drospirenone and ethinyl estradiol tablets, USP)[1].
- AARP: AARP Report Finds Top 10 Prescription Drug Price Hikes[2].
- Fortune Business Insights: Contraceptive Drugs Market Size, Share | Global Report, 2032[3].
- GlobeNewswire: Global Contraceptive Drugs Market Size To Worth USD 40.08 Billion By 2033[4].
- ASPE - HHS.gov: Inflation Reduction Act Research Series - ASPE - HHS.gov[5].
More… ↓
